Eli Lilly, on the verge of the first consumer ad campaign for its Zepbound weight loss drug ... that people should eat less ...

Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...

maker of blockbuster obesity drug Zepbound. The Big Pharma partnered with the OAC to produce a set of images deemed to be more accurate and respectful in their portrayals of people with obesity ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...

Similar to Lilly's weight loss treatments (Mounjaro and Zepbound), VK2735 is a dual glucagon-like peptide ... it's important ...

Let's find out. Eli Lilly developed a medicine called Zepbound to help with weight loss. It is one of the leading products in this niche, and it is currently posting incredibly fast-growing sales.

Eli Lilly's stock valuation sank by $100 billion Wednesday morning after the pharma giant reported third quarter earnings.

Celebrity endorsements have helped fuel excitement around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant weight loss. “People are ...

Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.